This combination of strategies resulted in four potential compounds to inhibit the DHFR enzyme: the antitumour drugs duvelisib and nilotinib, the anti-herpetic amenamevir, which is still in phase 3 clinical trials, and the dry eye syndrome drug lifitegrast. The gene discussed is DHFR; the disease is dry eye syndrome.